[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data
European Journal of Nuclear Medicine and Molecular Imaging · 2026-02 · 53 (3) · 2047-2053
DOI: 10.1007/s00259-025-07555-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 22.09.2025. Verfasst von Caroline Boursier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, CHRU Nancy, and Nancyclotep Imaging Platform, Nancy, F-54000, France. c.boursier@chru-nancy.fr. Hauptthemen laut MEDLINE: Meningioma, Organometallic Compounds, Octreotide, Meningeal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses. METHODS: Patients with refractory and progressive meningiomas treated with [177Lu]Lu-DOTATATE from 2021 to 2024 were retrospectively included. Association analyses of clinical factors, WHO grade, prior therapy (surgery, radiation, systemic therapy: bevacizumab or a combination of octreotide/everolimus), 3D-MRI volume and pretreatment PET parameters with 6-month progression-free survival (PFS-6), as defined by the 3D-RANO criteria, were performed. Growth rates obtained via MRI and tumor absorbed doses (TAD) were also calculated. RESULTS: Sixteen patients (60 [55;68] years old) underwent 4 [2;4] cycles of [177Lu]Lu-DOTATATE, with a TAD/cycle of 0.45 [0.30;0.83] Gy/GBq/cycle. Only prior systemic therapy was found as a risk factor for PFS-6 (p ≤ 0.05), with an impact on tumor growth rate (TGR) (4 vs. 12 patients, + 125% vs. -107%, p < 0.01). For the 12 patients without any prior systemic therapy, the PFS-6 was 67% (8/12 patients) whereas it was 0% in the other group, those with prior systemic therapy. No associations between the TAD and difference in the TGR before/after SSTR-RT were observed in the overall population (p = 0.10) or in the population of patients without any prior therapy (p = 0.72). CONCLUSION: [177Lu]Lu-DOTATATE appears effective in refractory meningiomas with no prior systemic therapy, even if the TADs are relatively low. [177Lu]Lu-DOTATATE should be proposed as early as possible in the treatment course of refractory meningiomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, CHRU Nancy, and Nancyclotep Imaging Platform, Nancy, F-54000, France. c.boursier@chru-nancy.fr.
- Université de Lorraine, IADI, INSERM U1254, Nancy, F-54000, France. c.boursier@chru-nancy.fr.
- Université de Lorraine, IADI, INSERM U1254, Nancy, F-54000, France.
- CHRU-Nancy, Université de Lorraine, CIC 1433, Innovation Technologique, Inserm, Nancy, F-54000, France.
- Department of Nuclear Medicine, CHRU Nancy, and Nancyclotep Imaging Platform, Nancy, F-54000, France.
- Department of Neuro-Oncology, Université de Lorraine, CHRU Nancy, Nancy, F-54000, France.
ORCID-Profile: Caroline Boursier
Zitieren
APA
Boursier, C., Zaragori, T., Garabedian, N., Blonski, M., Obara, T., Taillandier, L., Imbert, L., & Verger, A. (2026). [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. European Journal of Nuclear Medicine and Molecular Imaging, 53(3), 2047-2053. https://doi.org/10.1007/s00259-025-07555-x
Vancouver
Boursier C, Zaragori T, Garabedian N, Blonski M, Obara T, Taillandier L, et al. [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(3):2047-2053. doi:10.1007/s00259-025-07555-x
BibTeX
@article{Boursier2026,
author = {Boursier, Caroline and Zaragori, Timothée and Garabedian, Nicolas and Blonski, Marie and Obara, Tiphaine and Taillandier, Luc and Imbert, Laetitia and Verger, Antoine},
title = {[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {3},
pages = {2047--2053},
doi = {10.1007/s00259-025-07555-x}
}
EUVIMED